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Purpose: To assess whether contrast material–enhanced ultrasonogra-
phy (US) can be used to differentiate responders from nonre-
sponders among patients with clinically active Crohn disease 
after 6 weeks of pharmacologic treatment.
Materials and 
Methods:
This prospective study was approved by our ethics commit-
tee, and written informed consent was obtained from all pa-
tients. Fifty consecutive patients (26 men and 24 women; mean 
age, 34.76 years 6 9) with a proved diagnosis of active Crohn 
disease who were scheduled to begin therapy with biologics (in-
fliximab or adalimumab) were included, with enrollment from 
June 1, 2013, to June 1, 2015. In each patient, the terminal 
ileal loop was imaged with contrast-enhanced US before the 
beginning and at the end of week 6 of pharmacologic treatment. 
Time-intensity curves obtained in responders (those with a de-
crease in the Crohn disease endoscopic index of severity score 
of 25–44 before treatment to 10–15 after treatment, an inflam-
matory score ,7, and/or a decrease 70 in the Crohn disease 
activity index score compared with baseline) and nonresponders 
were compared with Mann-Whitney test.
Results: Responders (n = 31) and nonresponders (n = 19) differed (P , 
.05) in the percent change of peak enhancement (240.78 6 62.85 
vs 53.21 6 72.5; P = .0001), wash-in (234.8 6 67.72 vs 89.44 
6 145.32; P = .001) and washout (25.64 6 130.71 vs 166.83 6 
204.44; P = .002) rate, wash-in perfusion index (242.29 6 59.21 
vs 50.96 6 71.13; P = .001), area under the time-intensity curve 
(AUC; 246.17 6 48.42 vs 41.78 6 87.64; P = .001), AUC during 
wash-in (243.93 6 54.29 vs 39.79 6 70.85; P = .001), and AUC 
during washout (249.36 6 47.42 vs 42.65 6 97.09; P = .001). Re-
sponders and nonresponders did not differ in the percent change 
of rise time (5.09 6 49.13 vs 6.24 6 48.06; P = .93) and time to 
peak enhancement (8.82 6 54.5 vs 10.21 6 43.25; P = .3).
Conclusion: Analysis of time-intensity curves obtained after injection of mi-
crobubble contrast material 6 weeks after beginning pharmaco-
logic treatment can be used to differentiate responders from non-
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needed to avoid prolonged expensive 
and ineffective treatments in patients 
who have no chance to respond to 
treatment. The aim of this study was 
to assess whether contrast-enhanced 
US can be used to differentiate re-
sponders from nonresponders among 
patients with clinically active Crohn 




This prospective observational study 
was approved by the ethics committee 
of our institute, and written informed 
consent was obtained from all patients. 
During a 24-month period (from June 1, 
2013, to June 1, 2015), we recruited all 
patients with a biopsy-proved diagnosis 
of Crohn disease, a history of Crohn 
disease with disease activity from a 
maximal time period of 3 months, and 
involvement of the terminal ileum at 
endoscopy with serial deep mucosal bi-
opsy who were scheduled to undergo 
biologic drug therapy (infliximab or 
adalimumab) either with or without 
corticosteroids to reduce Crohn disease 
activity in the acute phase as planned 
by the referring gastroenterologist. The 
following inclusion criteria were used: 
(a) age greater than 18 years and (b) 
moderately or severely active Crohn 
(1,2). Computed tomography (CT) and 
magnetic resonance (MR) imaging can 
depict the transmural and extraint-
estinal extent of Crohn disease, even 
though they require large amounts of 
enteric contrast material (6–12). More-
over, CT exposes the patient to high ra-
diation doses, especially if it is repeated 
during a strict follow-up schedule, as in 
patients who undergo surveillance dur-
ing pharmacologic treatment.
Previous studies showed the capa-
bilities of contrast material–enhanced 
ultrasonography (US) for classifying 
Crohn disease severity and differenti-
ating responders from nonresponders 
with time-intensity curve analysis be-
fore and after beginning pharmaco-
logic treatment (13–18). In particular, 
a recent article proposed an early eval-
uation of time-intensity curves after 
microbubble injection (at 1 month and 
at 3 and 12 months after initiation of 
the treatment) in patients with Crohn 
disease undergoing pharmacologic 
treatment, while usually the clinical 
assessment of therapeutic outcome is 
performed at 12 weeks (18). In this 
study, only the absolute values of the 
different kinetic parameters were com-
pared, whereas the percent change of 
each kinetic parameter before versus 
after beginning pharmacologic treat-
ment, which could represent a better 
method of differentiating responders 
from nonresponders and reduce the 
wide interpatient variability, was not 
assessed (18). Moreover, analysis of 
a larger patient population with iden-
tification of potential thresholds for 
each kinetic parameter to differenti-
ate responders from nonresponders is 
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Advances in Knowledge
 n Patients with Crohn disease who 
respond to therapy can be differ-
entiated from nonresponders on 
the basis of the percent change 
of peak enhancement (240.78 6 
62.85 vs 53.21 6 72.5; P , .05) 
as measured before and 6 weeks 
after beginning pharmacologic 
therapy.
 n Patients with Crohn disease who 
respond to therapy can be differ-
entiated from nonresponders on 
the basis of the percent change 
of the area under the time-inten-
sity curve (AUC) (246.17 6 
48.42 vs 41.78 6 87.64; P , 
.05), AUC during wash-in 
(243.93 6 54.29 vs 39.79 6 
70.85; P , .05), and AUC during 
washout (249.36 6 47.42 vs 
42.65 6 97.09; P , .05) as mea-
sured before and 6 weeks after 
beginning pharmacologic therapy.
Implications for Patient Care
 n Contrast-enhanced US may 
become useful for monitoring the 
efficacy of specific pharmacologic 
therapies in patients with Crohn 
disease.
 n Adjusting pharmacologic treat-
ment on the basis of contrast-
enhanced US findings may help 
avoid inappropriate prolonged 
treatment with expensive biologic 
drugs.
In patients with Crohn disease, es-pecially in clinical trials, the thera-peutic outcome of pharmacologic 
treatment is assessed with the Crohn 
disease activity index (CDAI) (1–3). 
Unfortunately, the CDAI has low spec-
ificity because it is mainly based on 
subjective symptoms, whereas the ad-
justment of pharmacologic treatment 
should be based on objective measures 
of inflammatory activity to avoid in-
appropriate prolonged treatment (3). 
Corticosteroids and/or biologic drugs 
are effective in treating patients with 
clinically active Crohn disease, even 
though biologic drugs are expensive, 
present potential toxicities, and often 
fail to reduce Crohn disease activity (4). 
Hence, a reliable and early assessment 
of the pharmacologic effect is necessary 
to identify patients who respond to the 
treatment (5).
Endoscopy (ileocolonoscopy) rep-
resents the reference standard for the 
assessment of Crohn disease inflamma-
tory activity (5). However, endoscopy 
does not show the transmural extent 
of Crohn disease, and intubation of the 
distal ileum can be completed in only 
80% of patients with Crohn disease 
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of unfeasible intubation of the distal 
ileum at ileum colonoscopy and, for 
this reason, were not classified as be-
ing a responder or a nonresponder (n 
= 2); ileal disease not appreciable at US 
(n = 2), corresponding to wall thick-
ness of the terminal ileal loop of less 
than 3 mm; involvement of ileal tracts 
other than the terminal tract (n = 5); 
and insufficient clinical follow-up (, 12 
weeks calculated after beginning phar-
macologic treatment, with the day on 
which the new treatment was begun 
considered day 0; n = 6). Thus, 50 pa-
tients (26 men and 24 women; mean 
age, 34.76 years 6 9) with a history 
of active Crohn disease of 1–3 months 
(mean, 2 months) and ileum (n = 46) 
or ileum and colon (n = 4) involvement 
were included in the study (Fig 1). 
These patients underwent specific an-
ti-inflammatory treatment on the basis 
of whether they underwent biologic 
drug (n = 20 [infliximab, n = 15; adalim-
umab, n = 5]) or biologic drug and cor-
ticosteroid (n = 30 [infliximab, n = 17; 
adalimumab, n = 13]) therapy (Table 1). 
Among patients who underwent bio-
logic drug and corticosteroid therapy 
from the beginning of disease activity 
(n = 30), 19 were not taking steroids at 
the 6th week, while 11 were still taking 
low-dose corticosteroids (10–15 mg/day 
of prednisone).
US Examination
From 1 to 15 days before the beginning 
and within 7 days after the end of week 
6 of pharmacologic treatment (42–49 
days), each patient underwent US of 
the terminal ileal loop. After a fast of 
at least 6 hours, the terminal ileal loop 
was imaged by a diagnostic radiologist 
with 10 years of experience in abdomi-
nal US before and after intravenous ad-
ministration of a single bolus of 4.8 mL 
of sulfur hexafluoride–filled microbub-
bles (SonoVue; Bracco, Milan, Italy) 
into a peripheral arm vein (duration of 
1–2 seconds) followed by a 10-mL 0.9% 
saline flush.
US was performed with a broadband 
256-element linear-array transducer 
(L12–5 and 5–12 MHz, 50 3 10 mm; 
Philips Healthcare, Bothell, Wash) and 
an iU22 xMATRIX US System (Philips). 
Sixty-five patients were initially in-
cluded in this study. Fifteen of these 
patients were finally excluded because 
disease involving the terminal ileal loop 
as seen at endoscopy and/or with a 
CDAI score greater than 220 (19).
Figure 1
Figure 1: Flow diagram shows the study group. CD = Crohn disease.
Table 1
Characteristics of Responders versus Nonresponders
Characteristic Responders Nonresponders P Value
Age (y)* 32.74 (22–65) 30.94 (19–42) .02
 Men 35.24 (22–65) … ...
 Women 34.74 (19–52) … ...
Sex …
 Male 15 11 .57
 Female 16 8 .57
Body mass index* 22.1 (20–24) 22.3 (20–26) .6
Disease type
 Nonstricturing and nonpenetrating 5 5 .99
 Structuring 22 13 .51
 Penetrating 4 1 …
Disease duration (y)* 6 (1–10) 6 (1–10) .99
Active disease duration (mo)* 2 (1–3) 2 (1–3) .99
Disease location
 Ileum 31 15 .001
 Ileo-colon 0 4 .008
Medication
Biologics and corticosteroids 15 15 .99
 Infliximab 8 9 …
 Adalimumab 7 6 …
Adalimumab only 3 2 .7
Infliximab only 13 2 .057
Note.—Unless otherwise indicated, data are numbers of patients.
* Data are the mean, and data in parentheses are the range.
Radiology: Volume 281: Number 2—November 2016 n radiology.rsna.org 609
ULTRASONOGRAPHY: Time-Intensity Curves Can Differentiate among Patients with Active Crohn Disease Quaia et al
tangent intersects the x-axis), time to 
peak enhancement, wash-in rate (max-
imum slope, tangent at the ascending 
part of the curve), washout rate (min-
imum slope, tangent at the descending 
part of the curve), AUC, wash-in perfu-
sion index (AUC during wash-in divided 
by rise time), AUC during wash-in, and 
AUC during washout. Data outliers 
were included in the analysis. In each 
patient, the percent change (post – pre 
3 100/pre, with “pre” and “post” refer-
ring to the linear value of each param-
eter measured in the bowel wall and 
adjacent mesentery before and 6 weeks 
after beginning pharmacologic therapy) 
of each kinetic parameter was related 
to the therapeutic outcome.
Therapeutic Outcome
Patients were followed up at 6, 12, 18, 
24, and 30 weeks, with redetermina-
tion of CDAI. Data for determining 
the CDAI score were collected for 7 
days by means of a diary card that was 
completed by the patient on a daily ba-
sis. Endoscopy, including examination 
of the large bowel and the distal part 
of the small bowel, was performed at 
least once from 10–12 weeks (mean, 
11.2 weeks) after beginning pharma-
cologic therapy to determine the final 
classification of each patient as a re-
sponder or nonresponder.
Endoscopy, including examination 
of the large bowel and terminal ileal 
loop, was performed by one gastro-
enterologist (M.S., with 30 years of 
experience) after the bowel was pre-
pared with polyethylene glycol, which 
was administered the previous day, 
and the patient fasted overnight. Im-
mediately after the procedure, an en-
doscopic score was assigned according 
to the Crohn disease endoscopic index 
of severity (22). Multiple deep mucosal 
biopsy specimens were obtained from 
different colonic segments and the ter-
minal ileal loop in all patients. By us-
ing the histologic acute inflammatory 
score, a score (up to a maximum of 13) 
was determined on the basis of grades 
for mucosal ulceration (grade 0–3), 
edema (grade 0–3), and the quantity 
(grade 0–3) and depth (grade 0–4) of 
neutrophilic infiltration by one of many 
4; Intel, Santa Clara, Calif) that was 
connected to the picture archiving and 
communication system and was used for 
quantitative analysis. If peristalsis-relat-
ed movements were evident in the im-
aged volume, the frames that appeared 
off-site to the reader were virtually ex-
cluded from quantitative analysis. Out-
of-plane images and images that pre-
ceded the arrival of contrast material 
in the bowel wall were excluded from 
processing both by the reference radiol-
ogist and independent readers.
VueBox (Bracco) is used to line-
arize compressed digital imaging and 
communications in medicine Joint 
Photographic Experts Group-format-
ted images before performing curve 
fitting and analysis through appli-
cation of an antilog function within 
the linear range of the microbubble 
concentration versus video-intensity 
relation. In each image, a manually 
defined polygonal (range, 4100–40 110 
pixels; mean, 21 430 pixels) region of 
interest (ROI) that encompassed the 
thickened ileal tract over the anterior 
wall and avoided the lumen, or that 
covered the entire bowel wall if the 
lumen was not visible and avoided the 
mesentery and artifacts along the en-
tire extension of the terminal ileum, 
was drawn and included in the screen 
field of view (Fig 2). A second ROI, 
which served as a potential internal 
reference and encompassed the ad-
jacent mesentery and excluded the 
ileal wall, was drawn. The US video 
intensity was measured in linear ar-
bitrary units, with the video intensity 
of pixels contained in each ROI ex-
pressed as mean plus or minus stan-
dard deviation. After the arrival of 
contrast material was automatically 
detected, time-intensity curves were 
fitted with a nonlinear least-squares 
regression method to a proprietary 
lognormal model (20,21). The quality 
of fit between the echo power signal 
and the theoretical curve was quanti-
fied with the least-square method.
The following kinetic parameters 
(Fig 3) were automatically calculated for 
each patient: peak enhancement, rise 
time (time to peak enhancement minus 
the time at which the maximum slope 
This linear transducer was selected be-
cause it produces high-resolution rect-
angular images that are suitable for the 
following quantitation procedure. Before 
administering US contrast material, the 
termimal ileal loop wall thickness was 
measured (in millimeters) at the level of 
the anterior wall, the depth of the ileal 
loop was measured from the leading se-
rosa edge of the anterior bowel wall up 
to the skin surface (in centimeters), and 
the absolute extension of the ileal tract 
involved was measured from the begin-
ning to the end of the involved ileal tract 
by the thickening of the anterior bowel 
wall (in centimeters).
Contrast-enhanced US was per-
formed by setting the following tech-
nical parameters at the same value 
before and after beginning pharma-
cologic treatment: power modulated 
pulse inversion technology; mechani-
cal index, 0.08; dynamic range, 65 dB; 
10–13 frames per second; echo-signal 
gain below noise visibility; signal persis-
tence turned on; and one focus below 
the level of the small bowel segment. 
One uncompressed digital imaging and 
communications in medicine multiframe 
cine clip (15 frames per second and 
2 minutes in duration) was acquired 
while the patient was breathing and 
transferred to the picture archiving and 
communication system in the radiology 
department.
Quantitative Analysis of US Images
One reference radiologist (E.Q., with 
15 years of experience in abdominal 
contrast-enhanced US) performed im-
age quantitative analysis of echo power 
by using a proprietary software pack-
age (VueBox, Version 4.3; Bracco, 
Geneva, Switzerland). Three sessions 
of analysis, each lasting 3 days, were 
necessary to complete the analysis. To 
assess interreader variability, two other 
blinded independent readers (R.A. 
and A.G.G., with 5 and 10 years of 
experience in abdominal imaging and 
contrast-enhanced US, respectively), 
performed quantitative analysis in a 
subgroup of 20 patients who were se-
lected by simple randomization.
Each digital cine clip was trans-
ferred to a personal computer (Pentium 
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pathologists, each with 10–20 years of 
experience (23).
A patient was classified as being a 
responder if the Crohn disease endo-
scopic index of severity score decreased 
from 25–44 before treatment to 10–15 
after treatment on the basis of ileum-
colonoscopy performed 10–12 weeks 
after beginning pharmacologic ther-
apy and the inflammatory score was 
lower than 7 and/or the CDAI score 
decreased by 70 or more compared 
with baseline; all other patients were 
classified as being nonresponders (24). 
In patients who were classified as re-
sponders, pharmacologic treatment was 
either maintained or increased depend-
ing on whether an increase in the CDAI 
was identified in the following weeks. In 
nonresponders, either the drug or drug 
combination was changed or treatment 
was intensified by increasing the drug 
dosage.
Figure 2
Figure 2: US images show a manually defined polygonal ROI (green) encompassing the thickened ileal tract over the anterior wall and avoiding the lumen (or 
encompassing the entire bowel wall if the lumen was not visible) and mesentery. Artifacts are seen along the entire extension of the terminal ileum included in the 
field of view on the screen. A second ROI (yellow) that served as a potential internal reference was drawn, encompassing the adjacent mesentery and excluding the 
ileal wall. Blue line = entire region considered for analysis and motion correction.
Figure 3
Figure 3: Graph shows a time-intensity curve. AUC = area under the time-
intensity curve, AUCWI = AUC during wash-in, AUCWO = AUC during washout.
Radiology: Volume 281: Number 2—November 2016 n radiology.rsna.org 611
ULTRASONOGRAPHY: Time-Intensity Curves Can Differentiate among Patients with Active Crohn Disease Quaia et al
Results
The mean absolute extension of the 
small bowel segments involved in Crohn 
disease was 5 cm (range, 3–10 cm), 
with a mean depth of 2.5 cm (range, 
2–4 cm) from the skin surface. Among 
responders (n = 31), eight patients 
underwent dose escalation of the bio-
logic drug because of a moderate in-
crease in the CDAI (10–20 units) after 
12 weeks, while the remaining 23 pa-
tients maintained the drug dose; among 
nonresponders (n = 19), five patients 
underwent dose escalation of the bio-
logic drug, four underwent azathioprine 
therapy, and 10 underwent surgical 
intervention.
Table 2  shows the results of quanti-
tative analysis as the percent change of 
the different kinetic parameters in re-
sponders and nonresponders (Figs 4, 5). 
The quality of fit (expressed as a per-
centage) between the echo power sig-
nal and the theoretical lognormal curve 
before and after treatment was 93.76 
6 4.82 and 88.93 6 8.33, respectively, 
in responders and 96.26 6 2.32 and 
82.47 6 29.29, respectively, in non-
responders. Responders (n = 31) and 
nonresponders (n = 19) differed in the 
percent change of peak enhancement, 
wash-in and washout rates, wash-in 
perfusion index, AUC, AUC during wash 
-in, and AUC during washout (Fig 6). 
Responders and nonresponders did not 
each kinetic parameter (independent 
variables) and the therapeutic out-
come as responder (dependent out-
come variable). Variables with a P 
value of less than .05 at univariate 
analysis were simultaneously entered 
into multivariate logistic regression 
analysis to identify kinetic parameters 
that were potential independent pre-
dictors of outcome.
The nonparametric Spearman sign 
rank correlation coefficient (r) was 
used to assess the strength of relation-
ships between the CDAI, kinetic pa-
rameters and endoscopic grading, and 
the kinetic parameters measured in the 
terminal loop and adjacent mesentery. 
Interreader agreement was assessed 
with intraclass correlation coefficient.
Receiver operating characteristic 
curves were constructed for the kinetic 
parameters that revealed a significant 
difference between responders and 
nonresponders to determine the opti-
mum cut-off values in accordance with 
the method of DeLong et al (25). The 
method used to identify the better cut-
off value corresponds to the measure-
ment of the maximum vertical distance 
of the receiver operating characteristic 
curve from the point (x, y) on a diago-
nal line (the chance line) by maximiz-
ing sensitivity plus specificity across 
various cut-off points. For all tests, P 
, .05 was considered to indicate a sig-
nificant difference.
Statistical Analysis
Statistical analysis was performed 
with MedCalc, version 12.2.1 (MedCalc 
software, Mariakerke, Belgium). The 
minimal appropriate patient number 
(n = 45) to be included in the study 
was estimated by considering a statis-
tical power of 0.8, a significance crite-
rion of 0.05, and a minimum expected 
difference between responders and 
nonresponders in each percentage of 
30%. Standard deviation was consid-
ered for calculating patient sample size 
and was around a percentage variation 
of 50% on the basis of preliminary 
studies (16–18).
Descriptive statistics, including 
continuous variables, such as the age 
of male and female patients, body 
mass index, and disease duration in 
responders and nonresponders, were 
compared with Mann-Whitney U test 
for independent samples. Categoric 
variables, such as the percentage of 
stricturing and penetrating disease, 
disease location, and type of medica-
tion in responders and nonresponders, 
were compared with x2 test.
The percent change of the differ-
ent kinetic parameters measured in 
responders and nonresponders was 
compared with Mann-Whitney U test 
for independent samples. Separate 
univariate logistic regressions were 
conducted to determine the relation-
ship between the percent change of 
Table 2
Percent Change of the Different Kinetic Parameters in Responders and Nonresponders
Parameter
Responders Nonresponders
P ValueMean 6 SD 95% CI Mean 6 SD 95% CI
Peak enhancement 240.78 6 62.85 263.83, 217.72 53.21 6 72.5 18.26, 88.15 .0001
Rise time 5.09 6 49.13 212.92, 23.12 6.24 6 48.06 216.92, 29.41 .93
Time to peak enhancement 8.82 6 54.5 211.16, 28.81 10.21 6 43.25 210.63, 31.06 .3
Wash-in rate 234.8 6 67.72 259.64, 29.95 89.44 6 145.32 19.39, 159.48 .001
Washout rate 25.64 6 130.71 253.59, 42.3 166.83 6 204.44 68.29, 265.37 .002
Wash-in perfusion index 242.29 6 59.21 276.42, 246.72 50.96 6 71.13 16.68, 85.25 .001
AUC 246.17 6 48.42 263.93, 228.41 41.78 6 87.64 20.45, 84.02 .001
AUC during wash-in 243.93 6 54.29 263.86, 24.03 39.79 6 70.85 5.64, 73.94 .001
AUC during washout 249.36 6 47.42 266.75, 231.97 42.65 6 97.09 24.14, 89.45 .001
Note.—Average values of percent change = Post – Pre 3 100/Pre, where Pre is the linear value before pharmacologic treatment and Post is the linear value 6 weeks after beginning pharmacologic 
treatment. CI = confidence interval, SD = standard deviation.
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Figure 4
Figure 4:  Difference in the time-intensity curve profile of a 25-year-old man with Crohn disease who responded to infliximab therapy. Contrast-enhanced US 
images obtained, A, before and, B, 6 weeks after beginning pharmacologic therapy show the terminal ileal loop. ROIs were manually drawn over the anterior bowel 
wall (green) and adjacent mesentery (yellow). Corresponding time-intensity curves obtained after echo power quantitation by placing an ROI over the bowel wall 
(green) and in the adjacent mesentery (yellow), C, before and, D, 6 weeks after beginning pharmacologic therapy show the percent variation of AUC (237.47), AUC 
during wash-in (267.2), and AUC during washout (252.98) in the mural wall. Blue line = entire region considered for analysis and motion correction.
Figure 5
Figure 5: Difference in the time-intensity curve profile of a 45-year-old man with Crohn disease who did not respond to infliximab therapy. Contrast-enhanced US 
images obtained, A, before and, B, 6 weeks after beginning pharmacologic therapy show the terminal ileal loop. ROIs were manually drawn over the anterior bowel 
wall (green) and adjacent mesentery (yellow). Corresponding time-intensity curves obtained after echo power quantitation, C, before and, D, 6 weeks after beginning 
infliximab therapy show the percent variation of AUC (233.98), AUC during wash-in (190.88), and AUC during washout (256.95) in the mural wall. Persistent activity is 
also seen in the adjacent mesentery (yellow curve) in D. Blue line = entire region considered for analysis and motion correction.
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Neither rise time nor time to peak 
enhancement was found to predict ther-
apeutic outcome at univariate analysis, 
whereas all other kinetic parameters 
were found to predict therapeutic out-
come. No kinetic parameter was found 
to be an independent predictor of ther-
apeutic outcome at multivariate logistic 
regression (P = .058 to P = 0.76).
between the kinetic parameters mea-
sured in the terminal loop and adjacent 
mesentery ranged from 0.113 to 0.42 
(P = .21). The Spearman correlation 
coefficient between the CDAI and en-
doscopy ranged from 0.31 to 0.45 (P 
= .29). The AUC was related to both 
endoscopic grading (r = 0.77, P = .03) 
and CDAI score (r = 0.42, P = .04).
differ in the percent change of rise time 
and time to peak enhancement.
The percent change of the different 
kinetic parameters within the internal 
reference, which corresponded to the 
adjacent mesentery, ranged from 21.65 
to 93 in responders and from 262.39 to 
407.67 in nonresponders. The nonpara-
metric Spearman correlation coefficient 
Figure 6
Figure 6: Box plots show the percent change of different kinetic parameters in responders and nonresponders. The top and bottom of the boxes are the first and 
third quartiles, respectively. The length of the box represents the interquartile range, including 50% of the values. The line through the middle of each box represents 
the median. The error shows the minimum and maximum values (range). An outside value (separate point outliers) is defined as a value that is smaller than the lower 
quartile minus 1.5 times the interquartile range or that is larger than the upper quartile plus 1.5 times the interquartile range. The P values for each comparison are 
shown over the box plots. AUCWI = AUC during wash-in, AUCWO = AUC during washout, PE = peak enhancement, RT = rise time, TTP = time to peak enhancement, 
WIPI = wash-in perfusion index, WIR = wash-in rate, WOR = washout rate.
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nonresponders, whereas we found that 
other kinetic parameters (ie, peak en-
hancement, AUC during wash-in, and 
AUC during washout) may be used to 
differentiate responders from nonre-
sponders (15–17,28–31). In our study, 
we calculated the percent change of 
each kinetic parameter for each pa-
tient. Calculating the intrapatient per-
cent change for the different kinetic 
parameters limits variability and could 
allow a more reproducible comparison 
of the results between responders and 
nonresponders, which compensates for 
the extremely wide range of possible 
absolute values of the different param-
eters. Moreover, in this study, we in-
cluded a larger patient population and 
identified thresholds for each kinetic 
parameter to differentiate responders 
from nonresponders among patients 
with Crohn disease with high sensitiv-
ity and specificity. We also found that 
internal reference that corresponds to 
the adjacent mesentery is unreliable 
for data normalization, since the per-
cent variation of the different kinetic 
parameters has a low correlation with 
the percent variation in the bowel wall.
According to our results, echo 
power quantitative analysis should be 
used to differentiate responders from 
nonresponders among patients with 
Crohn disease, since it allows assess-
ment of mural enhancement. We sug-
gest that quantitative analysis of con-
trast-enhanced US cine clips should 
be routinely used in clinical practice to 
assess disease activity, as shown in our 
pharmacologic therapy may represent 
a reliable imaging technique for early 
assessment of Crohn disease in patients 
undergoing specific pharmacologic 
treatment to identify which patients 
have a chance to respond to ongoing 
pharmacologic treatment, change the 
pharmacologic treatment at an earlier 
date in nonresponders, and avoid in-
appropriate prolonged pharmacologic 
treatments that are expensive and may 
be toxic. Even though CT and MR en-
terography still represent the reference 
imaging techniques for grading Crohn 
disease activity, contrast-enhanced US 
may represent an alternative modality 
and, compared with the other modal-
ities, offers several advantages, includ-
ing low cost, portability, availability, 
lack of restrictions in performing fre-
quent serial examinations at short in-
tervals, and an absence of radiation 
exposure (12–18,26,27).
Previous studies showed the ca-
pabilities of contrast-enhanced US 
for classifying Crohn disease activity 
and differentiating inflammatory from 
fibrotic bowel lumen strictures (15–
17,28–31). In previous studies, patients 
underwent contrast-enhanced US 12 
weeks or more after beginning pharma-
cologic therapy, whereas the earlier as-
sessment proposed in this study could 
avoid prolonged expensive and ineffec-
tive treatments in patients who have no 
chance to respond to treatment (15–
17). In these previous studies, AUC was 
the main kinetic parameter that showed 
a difference between responders and 
The intraclass correlation coeffi-
cient between the quantification of the 
two readers ranged from 0.6 to 0.8. 
The intraclass correlation coefficient 
between the reference reviewer and 
the independent readers with 5 and 10 
years of experience was 0.6–0.7 and 
0.6–0.9, respectively. Table 3 shows 
that receiver operating characteristic 
curve analysis for identifying the opti-
mum cut-off value for peak enhance-
ment, AUC, AUC during wash-in, and 
AUC during washout had high sensi-
tivity (77.8%–86.1%) and specificity 
(85.7%–100%) for differentiating re-
sponders from nonresponders among 
patients with Crohn disease.
Discussion
In this prospective study, we found that, 
among patients with Crohn disease, 
early assessment (6 weeks after begin-
ning therapy) of the percent change of 
some kinetic parameters derived from 
time-intensity curve data obtained 
after injection of sulfur hexafluoride-
filled microbubble contrast material 
may be used to differentiate responders 
to pharmacologic therapy from non-
responders. We observed a very high 
quality of fit between the echo power 
signal and the theoretical lognormal 
curve both in responders and nonre-
sponders, which ensured reliable quan-
titative analysis.
According to our results, the as-
sessment of bowel wall perfusion with 
contrast-enhanced US after 6 weeks of 
Table 3
Areas under the Receiver Operating Characteristic Curve, Sensitivity, and Specificity of Percent Change to Differentiate Responders 
from Nonresponders
Parameter AUC Cut-off Value Sensitivity (%) Specificity (%)
Peak enhancement 0.893 (0.77, 0.96)  252.24 77.8 (60.8, 89.9) 100 (76.8, 100)
Wash-in rate 0.829 (0.69, 0.92)  228.23 86.1 (70.5, 95.3) 85.7 (57.2, 98.2)
Washout rate 0.889 (0.76, 0.96)  234.12 77.78 (60.8, 89.9) 100 (76.8, 100)
Wash-in perfusion index 0.893 (0.77, 0.96)  253.91 77.8 (60.8, 89.9) 100 (76.8, 100)
AUC 0.881 (0.75, 0.95)  226.49 86.1 (70.5, 95.3) 100 (76.8, 100)
AUC during wash-in 0.868 (0.64, 0.97)  217.69 77.8 (60.8, 89.9) 100 (76.8, 100)
AUC during washout 0.889 (0.76, 0.96)  231.72 86.1 (70.5, 95.3) 100 (76.8, 100)
Note.—Data in parentheses are 95% confidence intervals. The areas under the receiver operating characteristic curve are produced by the different cut-off values of the percent increase of AUC, AUC 
during wash-in, and AUC during washout. 
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and previous studies (19,33). However, 
it should be recognized that the qual-
ity of contrast-enhanced US cine clips 
depends on the experience level of the 
examining health care provider, the 
resolution of the US unit, and the loca-
tion and severity of Crohn disease, with 
limitations in examining obese patients 
and the proximal ileum and jejunum.
Our study had other limitations, 
as well. Being an observational study, 
there was variability of pharmacologic 
treatment, including the use of cortico-
steroids. Our exclusion criteria could 
have led to biased results. Contrast-
enhanced US was performed only in 
the terminal ileal loop; other ileal seg-
ments may have been more or less af-
fected with a more evident or absent 
response. Another limitation is that we 
used our own data to set the thresh-
olds that were tested for sensitivity and 
specificity, which may have overesti-
mated our results. Finally, calculations 
of contrast-enhanced US data were per-
formed in arbitrary units from a single 
machine and are not necessarily inter-
changeable with those from other US 
equipment. In conclusion, the analysis 
of time-intensity curves obtained after 
injection of microbubble contrast ma-
terial 6 weeks after beginning pharma-
cologic treatment can be used to differ-
entiate responders from nonresponders 
among patients with clinically active 
Crohn disease.
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